Filing Flows

Filing Flows › Companies › Enanta Pharmaceuticals › Cash flow

Enanta Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$10.0M in Q3 FY26 · −$36.9M over twelve months

Operating cash flow−$10.0M
Capital spending−$7K
Free cash flow−$10.0M

Analysis

In Q3 FY26, Enanta Pharmaceuticals generated −$10.0M of operating cash flow and spent $7K on capital projects, leaving free cash flow of −$10.0M. That is $27.3M less than in Q3 FY25 ($17.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$35.3M; the largest uses were operating cash flow ($35.3M), other investing ($17.4M), capital spending ($1.6M); besides operations, cash came from other financing ($42.7M), shares issued ($733K); the cash balance fell by $11.4M.

Operating cash flow was −$10.0M against net income of −$19.5M. The largest differences: stock-based pay +$3.7M, accrued liabilities +$3.3M, receivables +$1.3M.

Free cash flow

Enanta Pharmaceuticals: free cash flow by quarterEnanta Pharmaceuticals: free cash flow by quarter−$19.4MQ4 FY24−$25.5MQ1 FY25−$16.0MQ2 FY25$17.4MQ3 FY25−$7.9MQ4 FY25−$11.8MQ1 FY26−$7.2MQ2 FY26−$10.0MQ3 FY26
Operating cash flow less capital spending.
Enanta Pharmaceuticals: operating cash flow against capital spendingEnanta Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$10.4M$9.0MQ4 FY24−$16.8M$8.7MQ1 FY25−$13.5M$2.5MQ2 FY25$17.5M$155KQ3 FY25−$6.5M$1.5MQ4 FY25−$11.7M$143KQ1 FY26−$7.2M$15KQ2 FY26−$10.0M$7KQ3 FY26
Latest (Q3 FY26): Operating cash flow −$10.0M, Capital spending $7K.

Capital allocation, year by year

Enanta Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearEnanta Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY21: Operating cash flow −$70.0MFY21: Shares issued $3.6MFY21: Capital spending −$750K$3.6MFY21FY22: Operating cash flow −$84.8MFY22: Shares issued $21.3MFY22: Capital spending −$2.1M$21.3MFY22FY23: Operating cash flow −$103MFY23: Shares issued $2.2MFY23: Capital spending −$9.1M$2.2MFY23FY24: Operating cash flow −$78.8MFY24: Shares issued $147KFY24: Capital spending −$17.9M$147KFY24FY25: Operating cash flow −$19.3MFY25: Shares issued $145KFY25: Capital spending −$12.9M$145KFY25
Over these 5 years operating cash flow totalled −$356M; the largest uses were operating cash flow ($356M) and capital spending ($42.8M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$190M
Debtnone
Net cash$190M
Cash runway5.1 years

Enanta Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$36.9M a year at the current rate against $190M of cash and investments: a runway of about 5.1 years before any new financing.

Where the cash came from and went

Enanta Pharmaceuticals: sources (+) and uses (−) of cash, Q3 FY26Enanta Pharmaceuticals: sources (+) and uses (−) of cash, Q3 FY26Other investing$14.0MOperating cash flow−$10.0MOther financing−$6.0MCash drawn (+) / kept (−)$1.5MShares issued$492KCapital spending−$7K
Enanta Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 FY26Enanta Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 FY26Other financing$42.7MOperating cash flow−$35.3MOther investing−$17.4MCash drawn (+) / kept (−)$11.4MCapital spending−$1.6MShares issued$733KTaxes on employees’ shares−$412K

From profit to cash

Enanta Pharmaceuticals: net income to operating cash flow, Q3 FY26Enanta Pharmaceuticals: net income to operating cash flow, Q3 FY26Net income−$19.5MDepreciation & amortization$1.2MStock-based pay$3.7MReceivables$1.3MPayables−$1.1MAccrued liabilities$3.3MPrepaid and other assets−$769KOther liabilities$8KOperating cash flow−$10.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26−$10.0M−$7K$492K$1.5M−$10.0M
Q2 FY26−$7.2M−$15K$49K$2.5M−$7.2M
Q1 FY26−$11.7M−$143K$70.1M−$5.1M−$11.8M
Q4 FY25−$6.5M−$1.5M$51K$12.5M−$7.9M
Q3 FY25$17.5M−$155K—$15.4M$17.4M
Q2 FY25−$13.5M−$2.5M—$24.7M−$16.0M
Q1 FY25−$16.8M−$8.7M$94K−$47.1M−$25.5M
Q4 FY24−$10.4M−$9.0M$68K−$1.5M−$19.4M

Enanta Pharmaceuticals: income statement and cash flow

Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%. The chart follows the revenue to costs, profit and cash.

Enanta Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.